A hyperbranched polymer includes a hyperbranched, hydrophobic molecular core, respective low molecular weight polyethyleneimine chains attached to at least three branches of the hyperbranched, hydrophobic molecular core, and respective polyethylene glycol chains attached to at least two other branches of the hyperbranched, hydrophobic molecular core. Examples of the hyperbranched polymer may be used to form hyperbranched polyplexes, and may be included in DNA or RNA delivery systems.

This invention provides formulations for use in distributing RNAi molecules targeted to a human GST-π for treating a malignant tumor in a subject. The formulation can include nanoparticles composed of an ionizable lipid, a DSPE lipid, and additional lipids. A drug product can be made by lyophilization of the formulation. This invention further provides methods for ameliorating or treating a malignant tumor by administering a therapeutically effective amount of a formulation containing the RNAi agents.

Disclosed are bispecific compounds (degraders) that target α-synuclein protein for degradation. Also disclosed are pharmaceutical compositions containing the degraders and methods of using the compounds to treat neurodegenerative diseases.

Provided herein are combination therapies comprising an AKT inhibitor, a PD-L1 antibody, and taxane for use in treating MTNBC and locally advanced TNBC.

The present disclosure relates to tertiary amino lipidated and/or PEGylated cationic peptide compounds and complexes thereof with nucleic acids for endocellular delivery, methods for preparing the compounds and complexes, and methods for delivering polyanionic compounds to cells.

The present invention pertains to an inventive release mechanism for extracellular vesicle (EV)-mediated intracellular and intramembrane delivery of therapeutic polypeptides. More specifically, the invention relates to EVs comprising polypeptide constructs which comprise a therapeutic polypeptide releasably attached to an exosomal polypeptide. Furthermore, the present invention pertains to manufacturing methods, pharmaceutical compositions, medical uses and applications, and various other embodiments related to the inventive EVs.

The present invention pertains to an inventive release mechanism for extracellular vesicle (EV)-mediated intracellular and intramembrane delivery of therapeutic polypeptides. More specifically, the invention relates to EVs comprising polypeptide constructs which comprise a therapeutic polypeptide releasably attached to an exosomal polypeptide. Furthermore, the present invention pertains to manufacturing methods, pharmaceutical compositions, medical uses and applications, and various other embodiments related to the inventive EVs.

The present application relates to a use of a nitric oxide synthase pathway inhibitor in preparation of a medicine, wherein the medicine is used for preventing, relieving and/or treating gastrointestinal ischemia-reperfusion related distal injury in a subject. The present application further relates to a use of nitric oxide synthase for screening a medicine, wherein the medicine is used for preventing, relieving and/or treating gastrointestinal ischemia-reperfusion related distal injury in a subject. The present application further relates to a pharmaceutical composition containing the nitric oxide synthase pathway inhibitor and a method for preventing, relieving and/or treating gastrointestinal ischemia-reperfusion related distal injury in a subject.

The present application relates to a use of a nitric oxide synthase pathway inhibitor in preparation of a medicine, wherein the medicine is used for preventing, relieving and/or treating gastrointestinal ischemia-reperfusion related distal injury in a subject. The present application further relates to a use of nitric oxide synthase for screening a medicine, wherein the medicine is used for preventing, relieving and/or treating gastrointestinal ischemia-reperfusion related distal injury in a subject. The present application further relates to a pharmaceutical composition containing the nitric oxide synthase pathway inhibitor and a method for preventing, relieving and/or treating gastrointestinal ischemia-reperfusion related distal injury in a subject.

The present invention relates to recombinant virulence attenuated Gram-negative bacterial strains and its use in a method of treating cancer in a subject.